What is Asymchem Laboratories Tianjin Co Debt-to-Equity?
Asymchem Laboratories Tianjin CoASLTY 69 Debt-to-Equity is 0.02 as of Mar. 2026, which is 100% above its 10-year median of 0.01. GuruFocus rates ASLTY with a GF Score™ of 69/100 and a GF Value™ of $3.88 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 965 Biotechnology companies, Asymchem Laboratories Tianjin Co ranks better than 88.08% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Asymchem Laboratories Tianjin Co's Debt-to-Equity or its related term are showing as below:
ASLTY'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.12
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Asymchem Laboratories Tianjin Co was 0.12. The lowest was 0.00. And the median was 0.01.
ASLTY's Debt-to-Equity is ranked better than 88.08% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs ASLTY: 0.02
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Asymchem Laboratories Tianjin Co Debt-to-Equity Related Terms
Asymchem Laboratories Tianjin Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co Debt-to-Equity Chart
ASLTY vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co (ASLTY) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Asymchem Laboratories Tianjin Co and its competitors. This is 100% above median its historical median of 0.01. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #115 out of 965 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Asymchem Laboratories Tianjin Co's Debt-to-Equity too high?
Asymchem Laboratories Tianjin Co's current Debt-to-Equity of 0.02 is 100% above median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. Asymchem Laboratories Tianjin Co's value of 0.02 is 87.5% below this industry median. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #115 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #115 out of 965 companies for Debt-to-Equity. This places Asymchem Laboratories Tianjin Co in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Asymchem Laboratories Tianjin Co's value of 0.02 is 87.5% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.16, Asymchem Laboratories Tianjin Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asymchem Laboratories Tianjin Co's current Debt-to-Equity of 0.02 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Asymchem Laboratories Tianjin Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asymchem Laboratories Tianjin Co's current Debt-to-Equity is 0.02, which is 100% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.88, compared to a current price of $6.37 — trading 64.2% above its estimated fair value. The current Debt-to-Equity is 0.02, which is 100% above median its 10-year median of 0.01 and 87.5% below the Biotechnology industry median of 0.16. Asymchem Laboratories Tianjin Co's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $6.37 is trading 64.2% above its estimated GF Value™ of $3.88.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
Debt-to-Equity: 0.02 (100% above median its 10-year median of 0.01)
GF Value™: $3.88 vs. price of $6.37 (64.2% above fair value)
Industry Position: 87.5% below the Biotechnology median (#115 of 965)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Business Description
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
69GF Score
Get the complete analysis for ASLTY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
